CY1114650T1 - USE OF PRE-MEDICINES FOR OPTICAL INTELLIGENCE ADMINISTRATION - Google Patents
USE OF PRE-MEDICINES FOR OPTICAL INTELLIGENCE ADMINISTRATIONInfo
- Publication number
- CY1114650T1 CY1114650T1 CY20131101064T CY131101064T CY1114650T1 CY 1114650 T1 CY1114650 T1 CY 1114650T1 CY 20131101064 T CY20131101064 T CY 20131101064T CY 131101064 T CY131101064 T CY 131101064T CY 1114650 T1 CY1114650 T1 CY 1114650T1
- Authority
- CY
- Cyprus
- Prior art keywords
- medicines
- optical intelligence
- administration
- intelligence administration
- optical
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Σύνθεση για χρήση στην θεραπεία μιας οφθαλμικής πάθησης ή ασθένειας ενός ανθρώπινου όντος ή ενός ζώου που την έχει ανάγκη, που περιλαμβάνει χορήγηση με επιθετικά μέσα, κατά προτίμηση με ενδοφθάλμια ένεση, τουλάχιστον ενός προ-φαρμάκου ενός στεροειδούς.Composition for use in the treatment of an eye disease or disease of a human being or animal in need thereof, comprising administering by aggressive means, preferably by intraocular injection, at least one prodrug of a steroid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06290902A EP1864668B1 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
EP10177382.8A EP2319517B1 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114650T1 true CY1114650T1 (en) | 2016-12-14 |
Family
ID=49724909
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100153T CY1113750T1 (en) | 2006-06-01 | 2013-02-20 | USE OF PRE-MEDICATIONS FOR EYE INTRODUCTION |
CY20131101064T CY1114650T1 (en) | 2006-06-01 | 2013-11-27 | USE OF PRE-MEDICINES FOR OPTICAL INTELLIGENCE ADMINISTRATION |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100153T CY1113750T1 (en) | 2006-06-01 | 2013-02-20 | USE OF PRE-MEDICATIONS FOR EYE INTRODUCTION |
Country Status (4)
Country | Link |
---|---|
CY (2) | CY1113750T1 (en) |
ES (1) | ES2437160T3 (en) |
PT (1) | PT2319517E (en) |
SI (1) | SI2319517T1 (en) |
-
2006
- 2006-06-01 SI SI200631706T patent/SI2319517T1/en unknown
- 2006-06-01 PT PT10177382T patent/PT2319517E/en unknown
- 2006-06-01 ES ES10177382T patent/ES2437160T3/en active Active
-
2013
- 2013-02-20 CY CY20131100153T patent/CY1113750T1/en unknown
- 2013-11-27 CY CY20131101064T patent/CY1114650T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2437160T3 (en) | 2014-01-09 |
SI2319517T1 (en) | 2014-01-31 |
CY1113750T1 (en) | 2016-06-22 |
PT2319517E (en) | 2013-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122428T1 (en) | THERAPEUTIC MANAGEMENT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA WITH BISPECIFIC ANTIBODIES AGAINST CD3XCD19 | |
DK2319517T3 (en) | APPLICATION OF PRODRUGS TO OCULAR, INTRAVENOUS ADMINISTRATION | |
CY1120417T1 (en) | METHODS TO REDUCE BASEFLOW LEVELS | |
CY1121125T1 (en) | COMPOSITIONS FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION | |
CY1116424T1 (en) | ADENINIS PRODUCTION AS RISK RISK | |
CY1119649T1 (en) | EXTREMELY FREEZING AND / OR TERMINATION OF SUBSTANTIAL-CONDITIONAL SUBSTANTIAL DRUG RELEASE | |
MA51617A (en) | DRUG DELIVERY MECHANISM | |
CY1118731T1 (en) | ALVIGLUTIDIS PHARMACEUTICAL COMPOSITIONS | |
CY1120879T1 (en) | MULTIPLE INGREDIENT BIOACTIVE INTALCALINE RING | |
BR112012025581A2 (en) | sustained release reservoir implants for intracameral drug delivery | |
CY1113766T1 (en) | INDOLIDONES PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISEASES | |
CY1116927T1 (en) | TETROHYDROCANNABINOL PRODUCTS, COMPOSITIONS CONTAINING TETHYROCANNABINOL PRODUCTS AND METHODS OF USE | |
EA200901211A1 (en) | ANTIGENS OF C5 PROTEIN AND THEIR APPLICATION | |
CY1117603T1 (en) | LIXISENATIDE AS AN ADDITION TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES | |
DK2148670T3 (en) | Titration of tapentadol | |
CY1121865T1 (en) | OPHTHALMOLOGICAL COMPOSITIONS AND THEIR USE | |
AR057946A1 (en) | FORMULATION OF SUSTAINED RELEASE ZONISAMIDE | |
CY1117854T1 (en) | Peptide Pharmaceutical Form for Local Ophthalmic Use | |
CY1115136T1 (en) | USE OF CHITOSANTS TO INCREASE Nail Growth Rate | |
AR088585A1 (en) | A MEDICINAL PRODUCT TO TREAT THE PREVIOUS EYE DISEASE | |
HN2009003424A (en) | (OXAZOLIDINON-5-IL-METIL) -2-TIOFEN-CARBOXAMIDAS REPLACED AND ITS USE IN THE FIELD OF THE SANGUINEA COAGULATION | |
CY1117671T1 (en) | CLOSTRIDIUM DIFFICILE COMPLICATIONS FOR THERAPEUTIC DISEASE TREATMENT | |
AR061446A1 (en) | USE OF 1,7-DIMETHYLXANTINE FOR THE MANUFACTURE OF A NON-ANIOIOUS PSYCHOANALEPTIC DRUG FOR THE TREATMENT OF A NEUROPSYCHIATRIC DISORDER | |
CY1114757T1 (en) | OXAZINE PRODUCTS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | |
EA202091533A1 (en) | METHODS FOR TREATMENT OF DIABETES, HEPATITIS AND / OR INFLAMMATORY LIVER DISEASE |